Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ML224 (NCGC00242364) is a TSHR antagonist for the treatment of Graves' orbital disease and Graves' hyperthyroidism.
Description | ML224 (NCGC00242364) is a TSHR antagonist for the treatment of Graves' orbital disease and Graves' hyperthyroidism. |
Targets&IC50 | LHR:>30 μM, TSHR:2.1 μM, HEK293 cells:2.1 μM, FSHR:>30 μM |
In vitro | In human embryonic kidney 293 cells, ML224 exhibits a half-maximal inhibitory concentration (IC50) of 2.1 μM against TSHR after a 20-minute exposure, with a range of 0.001-100 μM. The half-maximal inhibitory concentrations against LH and FSH receptors exceed 30 μM[1]. |
In vivo | ML224(ANTAG3) 2 mg per mouse; administered through intraperitoneal infusion pump; once daily for 3 days) reduces serum FT4 levels and thyroid mRNA of TPO and NIS in mice subjected to prolonged TRH stimulation[1]. |
Synonyms | NCGC00242364, ANTAG3 |
Molecular Weight | 525.59 |
Formula | C31H31N3O5 |
CAS No. | 1338824-21-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (152.21 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ML224 1338824-21-7 GPCR/G Protein TSH Receptor NCGC 00242364 NCGC00242364 ML 224 ANTAG-3 ANTAG 3 NCGC-00242364 ANTAG3 ML-224 inhibitor inhibit